Catalyst Pharmaceutical Partners is a development-stage specialty pharmaceutical company engaged in developing and commercializing prescription drugs that target diseases and disorders of the central nervous system, including addiction and epilepsy. The company has two products in development, CPP-109 and CPP-115. Catalyst is currently evaluating CPP-109, its lead product and first-in-class GABA aminotransferase inhibitor candidate, for the treatment of cocaine addiction. Both products have received “Fast Track” status from the FDA for treating cocaine addiction. For more information, visit the company’s Web site at www.catalystpharma.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: